Clinical Comparison of Statins
| Statin | Typical Adult Dose | Relative LDL-C ↓ (%) | Metabolism / Pathway | Renal Adjustment | Major Drug Interactions | Clinical Pearls |
|---|---|---|---|---|---|---|
| Atorvastatin | 10–80 mg QD | High (≈ 40–55%) | CYP3A4 | No | Strong CYP3A4 inhibitors (clarithromycin, itraconazole), protease inhibitors, grapefruit | Good for high-intensity; long half-life supports evening or anytime dosing |
| Rosuvastatin | 5–40 mg QD | High (≈ 45–60%) | Minimal CYP (OATP1B1) | CrCl < 30 mL/min: reduce dose | Gemfibrozil, cyclosporine; modest interactions | Potent LDL-C lowering; favorable in renal disease at adjusted doses |
| Simvastatin | 10–40 mg (max 40 mg) | Moderate-High (≈ 35–45%) | CYP3A4 | No | Strong CYP3A4 inhibitors (diltiazem, amiodarone); avoid with protease inhibitors | Limit dose due to myopathy risk with interacting drugs |
| Pravastatin | 10–80 mg QD | Moderate (≈ 30–40%) | Non-CYP (sulfation) | None formally required but caution in ↓ renal | Fewer interactions; safe with most cardio drugs | Good option if polypharmacy/interaction concerns |
| Lovastatin | 20–80 mg QD | Moderate (≈ 30–40%) | CYP3A4 | No | Strong CYP3A4 inhibitors; avoid heavy alcohol | Often dosed with evening meal for absorption |
| Fluvastatin | 20–80 mg QD/BID | Low-Moderate (≈ 20–35%) | CYP2C9 | No | CYP2C9 inhibitors (fluconazole) | Lower potency; useful if interaction concern with CYP3A4 |
| Pitavastatin | 1–4 mg QD | Moderate-High (≈ 35–50%) | Minimal CYP | No | Minimal interactions; avoid cyclosporine | Good option when high potency needed with low interaction risk |
| Cerivastatin | Withdrawn | — | — | — | — | Withdrawn due to rhabdomyolysis risk — included for historical context |
Key Clinical Considerations
Intensity Categories (for CVD risk reduction)
- High-intensity statins (≥50% LDL-C ↓):
- Atorvastatin 40–80 mg, Rosuvastatin 20–40 mg
- Moderate-intensity statins (≈30–50% LDL-C ↓):
- Simvastatin 20–40 mg, Pravastatin 40–80 mg, Lovastatin 40 mg, Fluvastatin 80 mg, Pitavastatin 2–4 mg
Pharmacokinetics & Interactions
CYP Pathway Summary
- CYP3A4 substrates: Atorvastatin, Simvastatin, Lovastatin → many interactions
- CYP2C9 substrate: Fluvastatin → fewer but notable with fluconazole
- Minimal CYP: Rosuvastatin, Pravastatin, Pitavastatin → lower interaction risk
Common CYP3A4 inhibitors increasing statin levels / myopathy risk:
- Clarithromycin/erythromycin
- Itraconazole/ketoconazole
- Protease inhibitors (HIV)
- Grapefruit juice
Statin transporter interactions:
- OATP1B1: Rosuvastatin/Pravastatin influenced by inhibitors like cyclosporine*
*Note: Rosuvastatin dose reduction recommended with cyclosporine.
Special Populations
Renal Impairment
- Rosuvastatin: requires dose reduction (CrCl < 30 mL/min)
- Other statins generally no formal renal adjustment, but clinical judgment advised for frail/elderly
Hepatic Impairment
- All statins: use caution; avoid in active liver disease / unexplained persistent transaminase elevation
Adverse Effects & Monitoring
- Myopathy / Rhabdomyolysis — rare but serious; ↑ risk with interacting drugs
- Transaminase elevations — baseline LFTs; repeat if symptomatic
- New-onset diabetes risk — small increase at high intensity
- CK measurement — only if muscle symptoms
Dosing Tips per Pharmacist
- Simvastatin 80 mg restricted — high myopathy risk; avoid starting new therapy at this dose
- Evening dosing: Shorter-acting statins (simva, lova, fluvastatin) may be more effective at night
- Rosuvastatin/Atorvastatin: longer half-life → flexible dosing
- Statin + fibrate: gemfibrozil + statin ↑ myopathy risk → avoid combination
Drug–Drug Interaction Scenarios
| Concomitant Drug | Statin Risk | Management |
|---|---|---|
| Clarithromycin | ↑ Simva/Atorva/Lova levels | Hold statin or choose low-interaction agent |
| Amiodarone | ↑ Simvastatin levels | Limit simva ≤ 20 mg |
| Cyclosporine | ↑ Rosuvastatin | Reduce rosuvastatin dose |
| Gemfibrozil | ↑ risk myopathy (esp. with statins) | Prefer fenofibrate; avoid gemfibrozil combo |